Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line

A. F. Sobrero, J. R. Bertino

Research output: Contribution to journalArticlepeer-review

Abstract

We studied the cell killing effects of cisplatin (CDDP), 3',5'-dichloromethotrexate (DCM), and different combinations of these drugs in a human colon carcinoma line (HCT-8). Using a clonogenic assay, the ED50 values for DCM were 3, 0.3, and 0.05 μM after 4-, 24-, and 48-hour exposure, respectively, while cell kill induced by CDDP was less time-dependent (ED50 values: 16, 7.8, 3.3, and 2.8 μM after 2-hour, 4-hour, 24-hour, and continuous incubation, respectively). Sequential exposure of these cells to DCM followed by CDDP resulted in synergism at every dose studied. The synergy was maximal with short DCM pretreatment intervals and decreased with increasing lengths of exposure to the antifol. In contrast, simple additive effects were observed when DCM was given together with or following CDDP. Considering the significant hepatic inactivation of both these compounds, our in vitro data encourage the design of clinical protocols with the sequence DCM → CDDP for hepatic arterial infusion treatment of liver metastasis from colon cancer.

Original languageEnglish
Pages (from-to)279-283
Number of pages5
JournalCancer Treatment Reports
Volume69
Issue number3
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line'. Together they form a unique fingerprint.

Cite this